$SCYX
SCYNEXIS INC

2024 Q3 Form 10-Q Financial Statement

#000095017024093856 Filed on August 08, 2024

View on sec.gov

Income Statement

Concept 2024 Q3 2024 Q2
Revenue $660.0K $736.0K
YoY Change -62.52% -99.44%
Cost Of Revenue $0.00 $0.00
YoY Change -100.0% -100.0%
Gross Profit $660.0K $736.0K
YoY Change -52.86% -99.44%
Gross Profit Margin 100.0% 100.0%
Selling, General & Admin $2.907M $3.166M
YoY Change -42.02% -57.64%
% of Gross Profit 440.45% 430.16%
Research & Development $8.073M $6.807M
YoY Change 24.85% -3.31%
% of Gross Profit 1223.18% 924.86%
Depreciation & Amortization $0.00 $0.00
YoY Change -100.0% -100.0%
% of Gross Profit 0.0% 0.0%
Operating Expenses $10.98M $9.973M
YoY Change -7.41% -33.25%
Operating Profit -$10.32M -$9.237M
YoY Change 2.2% -107.93%
Interest Expense $366.0K $197.0K
YoY Change 72.64% -84.23%
% of Operating Profit
Other Income/Expense, Net $7.117M -$5.221M
YoY Change -14.67% -190.86%
Pretax Income -$3.203M -$14.46M
YoY Change 82.3% -111.83%
Income Tax -$395.0K $0.00
% Of Pretax Income
Net Earnings -$2.808M -$14.46M
YoY Change 59.82% -111.83%
Net Earnings / Revenue -425.45% -1964.4%
Basic Earnings Per Share -$0.06 -$0.30
Diluted Earnings Per Share -$0.06 -$0.30
COMMON SHARES
Basic Shares Outstanding 37.86M 37.78M
Diluted Shares Outstanding 48.62M 48.51M

Balance Sheet

Concept 2024 Q3 2024 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments $68.83M $73.04M
YoY Change -21.88% -14.62%
Cash & Equivalents $28.73M $25.99M
Short-Term Investments $40.10M $47.04M
Other Short-Term Assets $953.0K $554.0K
YoY Change -49.71% -50.09%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $80.46M $94.58M
YoY Change -37.45% -35.01%
LONG-TERM ASSETS
Property, Plant & Equipment $2.163M $2.233M
YoY Change -9.88% -10.1%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments $16.12M $10.66M
YoY Change -5.75% 68.2%
Other Assets $296.0K $338.0K
YoY Change 1084.0% 428.13%
Total Long-Term Assets $18.58M $13.23M
YoY Change -6.68% 41.84%
TOTAL ASSETS
Total Short-Term Assets $80.46M $94.58M
Total Long-Term Assets $18.58M $13.23M
Total Assets $99.04M $107.8M
YoY Change -33.33% -30.38%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $4.955M $5.350M
YoY Change 41.98% 56.62%
Accrued Expenses $5.508M $5.498M
YoY Change -42.28% -23.53%
Deferred Revenue
YoY Change
Short-Term Debt $13.23M $12.78M
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $25.72M $25.23M
YoY Change 53.18% 56.16%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00
YoY Change -100.0% -100.0%
Other Long-Term Liabilities $14.79M $22.17M
YoY Change -47.18% -34.78%
Total Long-Term Liabilities $14.79M $22.17M
YoY Change -62.84% -51.41%
TOTAL LIABILITIES
Total Short-Term Liabilities $25.72M $25.23M
Total Long-Term Liabilities $14.79M $22.17M
Total Liabilities $40.51M $47.40M
YoY Change -28.37% -23.27%
SHAREHOLDERS EQUITY
Retained Earnings -$372.1M -$369.3M
YoY Change 10.84% 10.6%
Common Stock
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $58.53M $60.41M
YoY Change
Total Liabilities & Shareholders Equity $99.04M $107.8M
YoY Change -33.33% -30.38%

Cashflow Statement

Concept 2024 Q3 2024 Q2
OPERATING ACTIVITIES
Net Income -$2.808M -$14.46M
YoY Change 59.82% -111.83%
Depreciation, Depletion And Amortization $0.00 $0.00
YoY Change -100.0% -100.0%
Cash From Operating Activities $765.0K -$10.86M
YoY Change -93.84% -114.6%
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities $1.941M $1.372M
YoY Change -107.37% -121.49%
Cash From Investing Activities $1.941M $1.372M
YoY Change -107.37% -121.49%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 31.00K 0.000
YoY Change 3.33% -100.0%
NET CHANGE
Cash From Operating Activities 765.0K -10.86M
Cash From Investing Activities 1.941M 1.372M
Cash From Financing Activities 31.00K 0.000
Net Change In Cash 2.737M -9.488M
YoY Change -119.68% -130.24%
FREE CASH FLOW
Cash From Operating Activities $765.0K -$10.86M
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Entity Central Index Key
EntityCentralIndexKey
0001178253
dei Amendment Flag
AmendmentFlag
false
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q2
CY2024Q2 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2023Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2024-06-30
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2024
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-36365
dei Entity Registrant Name
EntityRegistrantName
SCYNEXIS, Inc.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
56-2181648
dei Entity Address Address Line1
EntityAddressAddressLine1
1 Evertrust Plaza
dei Entity Address Address Line2
EntityAddressAddressLine2
13th Floor
dei Entity Address City Or Town
EntityAddressCityOrTown
Jersey City
dei Entity Address State Or Province
EntityAddressStateOrProvince
NJ
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
07302-6548
dei City Area Code
CityAreaCode
201
dei Local Phone Number
LocalPhoneNumber
884-5485
dei Security12b Title
Security12bTitle
Common Stock, par value $0.001 per share
dei Trading Symbol
TradingSymbol
SCYX
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
dei Entity Shell Company
EntityShellCompany
false
CY2024Q3 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
37856463
CY2024Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
25994000
CY2023Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
34050000
CY2024Q2 us-gaap Short Term Investments
ShortTermInvestments
47044000
CY2023Q4 us-gaap Short Term Investments
ShortTermInvestments
40312000
CY2024Q2 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
1418000
CY2023Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
5548000
CY2024Q2 scyx License Agreement Receivable
LicenseAgreementReceivable
233000
CY2023Q4 scyx License Agreement Receivable
LicenseAgreementReceivable
2463000
CY2024Q2 us-gaap Contract With Customer Asset Net Current
ContractWithCustomerAssetNetCurrent
19509000
CY2023Q4 us-gaap Contract With Customer Asset Net Current
ContractWithCustomerAssetNetCurrent
19363000
CY2024Q2 us-gaap Restricted Cash Current
RestrictedCashCurrent
380000
CY2023Q4 us-gaap Restricted Cash Current
RestrictedCashCurrent
380000
CY2024Q2 us-gaap Assets Current
AssetsCurrent
94578000
CY2023Q4 us-gaap Assets Current
AssetsCurrent
102116000
CY2024Q2 us-gaap Investments
Investments
10657000
CY2023Q4 us-gaap Investments
Investments
23594000
CY2024Q2 us-gaap Deferred Costs
DeferredCosts
175000
CY2023Q4 us-gaap Deferred Costs
DeferredCosts
175000
CY2024Q2 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
163000
CY2023Q4 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
163000
CY2024Q2 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
2233000
CY2023Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
2364000
CY2024Q2 us-gaap Assets
Assets
107806000
CY2023Q4 us-gaap Assets
Assets
128412000
CY2024Q2 us-gaap Accounts Payable Current
AccountsPayableCurrent
5350000
CY2023Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
7149000
CY2024Q2 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
5498000
CY2023Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
7495000
CY2024Q2 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
1229000
CY2023Q4 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
1189000
CY2024Q2 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
372000
CY2023Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
340000
CY2024Q2 scyx Warrant Liabilities Current
WarrantLiabilitiesCurrent
0
CY2023Q4 scyx Warrant Liabilities Current
WarrantLiabilitiesCurrent
130000
CY2024Q2 scyx Convertible Debt And Derivative Liability Current
ConvertibleDebtAndDerivativeLiabilityCurrent
12784000
CY2023Q4 scyx Convertible Debt And Derivative Liability Current
ConvertibleDebtAndDerivativeLiabilityCurrent
0
CY2024Q2 us-gaap Liabilities Current
LiabilitiesCurrent
25233000
CY2023Q4 us-gaap Liabilities Current
LiabilitiesCurrent
16303000
CY2024Q2 us-gaap Deferred Revenue Noncurrent
DeferredRevenueNoncurrent
1817000
CY2023Q4 us-gaap Deferred Revenue Noncurrent
DeferredRevenueNoncurrent
2727000
CY2024Q2 us-gaap Warrants And Rights Outstanding
WarrantsAndRightsOutstanding
17962000
CY2023Q4 us-gaap Warrants And Rights Outstanding
WarrantsAndRightsOutstanding
21680000
CY2024Q2 scyx Convertible Debt And Derivative Liability
ConvertibleDebtAndDerivativeLiability
0
CY2023Q4 scyx Convertible Debt And Derivative Liability
ConvertibleDebtAndDerivativeLiability
12159000
CY2024Q2 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
2388000
CY2023Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
2581000
CY2024Q2 us-gaap Liabilities
Liabilities
47400000
CY2023Q4 us-gaap Liabilities
Liabilities
55450000
CY2024Q2 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2023Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2024Q2 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000
CY2023Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000
CY2024Q2 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2023Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2024Q2 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2023Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2024Q2 us-gaap Preferred Stock Value Outstanding
PreferredStockValueOutstanding
0
CY2023Q4 us-gaap Preferred Stock Value Outstanding
PreferredStockValueOutstanding
0
CY2024Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2023Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2024Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
150000000
CY2023Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
150000000
CY2024Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
37856463
CY2024Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
37856463
CY2023Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
37207799
CY2023Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
37207799
CY2024Q2 us-gaap Common Stock Value Outstanding
CommonStockValueOutstanding
41000
CY2023Q4 us-gaap Common Stock Value Outstanding
CommonStockValueOutstanding
40000
CY2024Q2 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
429659000
CY2023Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
428169000
CY2024Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-369294000
CY2023Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-355247000
CY2024Q2 us-gaap Stockholders Equity
StockholdersEquity
60406000
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
72962000
CY2024Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
107806000
CY2023Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
128412000
CY2024Q2 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
736000
CY2023Q2 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
131454000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
2109000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
132584000
CY2024Q2 scyx Cost Of Product Revenues
CostOfProductRevenues
0
CY2023Q2 scyx Cost Of Product Revenues
CostOfProductRevenues
426000
scyx Cost Of Product Revenues
CostOfProductRevenues
0
scyx Cost Of Product Revenues
CostOfProductRevenues
562000
CY2024Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
6807000
CY2023Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
7040000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
14019000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
13875000
CY2024Q2 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
3166000
CY2023Q2 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
7474000
us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
6835000
us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
12314000
CY2024Q2 us-gaap Operating Expenses
OperatingExpenses
9973000
CY2023Q2 us-gaap Operating Expenses
OperatingExpenses
14940000
us-gaap Operating Expenses
OperatingExpenses
20854000
us-gaap Operating Expenses
OperatingExpenses
26751000
CY2024Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-9237000
CY2023Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
116514000
us-gaap Operating Income Loss
OperatingIncomeLoss
-18745000
us-gaap Operating Income Loss
OperatingIncomeLoss
105833000
CY2024Q2 us-gaap Amortization Of Financing Costs And Discounts
AmortizationOfFinancingCostsAndDiscounts
421000
CY2023Q2 us-gaap Amortization Of Financing Costs And Discounts
AmortizationOfFinancingCostsAndDiscounts
1998000
us-gaap Amortization Of Financing Costs And Discounts
AmortizationOfFinancingCostsAndDiscounts
822000
us-gaap Amortization Of Financing Costs And Discounts
AmortizationOfFinancingCostsAndDiscounts
2256000
CY2024Q2 us-gaap Interest Income Other
InterestIncomeOther
1130000
CY2023Q2 us-gaap Interest Income Other
InterestIncomeOther
737000
us-gaap Interest Income Other
InterestIncomeOther
2402000
us-gaap Interest Income Other
InterestIncomeOther
1325000
CY2024Q2 us-gaap Interest Expense
InterestExpense
197000
CY2023Q2 us-gaap Interest Expense
InterestExpense
1249000
us-gaap Interest Expense
InterestExpense
403000
us-gaap Interest Expense
InterestExpense
2695000
CY2024Q2 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
5761000
CY2023Q2 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-8214000
us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-3848000
us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
13459000
CY2024Q2 us-gaap Gain Loss On Derivative Instruments Net Pretax
GainLossOnDerivativeInstrumentsNetPretax
28000
CY2023Q2 us-gaap Gain Loss On Derivative Instruments Net Pretax
GainLossOnDerivativeInstrumentsNetPretax
42000
us-gaap Gain Loss On Derivative Instruments Net Pretax
GainLossOnDerivativeInstrumentsNetPretax
196000
us-gaap Gain Loss On Derivative Instruments Net Pretax
GainLossOnDerivativeInstrumentsNetPretax
-364000
CY2024Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-5221000
CY2023Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
5746000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
5221000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-17449000
CY2024Q2 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-14458000
CY2023Q2 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
122260000
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-13524000
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
88384000
CY2024Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2023Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
523000
CY2024Q2 us-gaap Net Income Loss
NetIncomeLoss
-14458000
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
122260000
us-gaap Net Income Loss
NetIncomeLoss
-14047000
us-gaap Net Income Loss
NetIncomeLoss
88384000
CY2024Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.3
CY2023Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
2.56
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.29
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
1.85
CY2024Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.3
CY2023Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
2.46
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.29
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
1.82
CY2024Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
48511656
CY2023Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
47837393
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
48379256
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
47797731
CY2024Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
48511656
CY2023Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
49923361
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
48379256
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
49166251
us-gaap Profit Loss
ProfitLoss
-14047000
us-gaap Profit Loss
ProfitLoss
88384000
us-gaap Depreciation And Amortization
DepreciationAndAmortization
0
us-gaap Depreciation And Amortization
DepreciationAndAmortization
304000
us-gaap Share Based Compensation
ShareBasedCompensation
1464000
us-gaap Share Based Compensation
ShareBasedCompensation
1435000
us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
621000
us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
-100000
us-gaap Amortization Of Financing Costs And Discounts
AmortizationOfFinancingCostsAndDiscounts
822000
us-gaap Amortization Of Financing Costs And Discounts
AmortizationOfFinancingCostsAndDiscounts
2256000
us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-3848000
us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
13459000
us-gaap Gain Loss On Derivative Instruments Net Pretax
GainLossOnDerivativeInstrumentsNetPretax
196000
us-gaap Gain Loss On Derivative Instruments Net Pretax
GainLossOnDerivativeInstrumentsNetPretax
-364000
us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
131000
us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
110000
scyx Write Off Of Deferred Asset For Commitment Fees
WriteOffOfDeferredAssetForCommitmentFees
0
scyx Write Off Of Deferred Asset For Commitment Fees
WriteOffOfDeferredAssetForCommitmentFees
514000
scyx Prepayment Fee For Loan Payable Payment
PrepaymentFeeForLoanPayablePayment
263000
us-gaap Increase Decrease In Prepaid Expenses Other
IncreaseDecreaseInPrepaidExpensesOther
-4131000
us-gaap Increase Decrease In Prepaid Expenses Other
IncreaseDecreaseInPrepaidExpensesOther
165000
scyx Increase Decrease In License Agreement Receivable
IncreaseDecreaseInLicenseAgreementReceivable
-2230000
scyx Increase Decrease In License Agreement Receivable
IncreaseDecreaseInLicenseAgreementReceivable
25000000
scyx Increase Decrease In License Agreement Contract Asset
IncreaseDecreaseInLicenseAgreementContractAsset
146000
scyx Increase Decrease In License Agreement Contract Asset
IncreaseDecreaseInLicenseAgreementContractAsset
19249000
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
0
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
243000
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
0
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
4563000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-1759000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-2521000
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-1997000
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
1562000
us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
-870000
us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
4369000
us-gaap Increase Decrease In Other Operating Liabilities
IncreaseDecreaseInOtherOperatingLiabilities
-161000
us-gaap Increase Decrease In Other Operating Liabilities
IncreaseDecreaseInOtherOperatingLiabilities
-5904000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-14867000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
55475000
us-gaap Payments To Acquire Held To Maturity Securities
PaymentsToAcquireHeldToMaturitySecurities
10719000
us-gaap Payments To Acquire Held To Maturity Securities
PaymentsToAcquireHeldToMaturitySecurities
26941000
us-gaap Proceeds From Sale And Maturity Of Held To Maturity Securities
ProceedsFromSaleAndMaturityOfHeldToMaturitySecurities
17545000
us-gaap Proceeds From Sale And Maturity Of Held To Maturity Securities
ProceedsFromSaleAndMaturityOfHeldToMaturitySecurities
20557000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
6826000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-6384000
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
4000
scyx Payments Of Deferred Offering Costs
PaymentsOfDeferredOfferingCosts
40000
scyx Payments Of Deferred Offering Costs
PaymentsOfDeferredOfferingCosts
0
us-gaap Repayments Of Short Term Debt
RepaymentsOfShortTermDebt
36383000
scyx Payment Of Loan Payable Prepayment Fee
PaymentOfLoanPayablePrepaymentFee
263000
us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans
25000
us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans
4000
scyx Payments For Proceeds From Repurchase Of Shares To Satisfy Tax Withholdings
PaymentsForProceedsFromRepurchaseOfSharesToSatisfyTaxWithholdings
0
scyx Payments For Proceeds From Repurchase Of Shares To Satisfy Tax Withholdings
PaymentsForProceedsFromRepurchaseOfSharesToSatisfyTaxWithholdings
-18000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-15000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-36620000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
-8056000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
12471000
CY2023Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
34593000
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
46032000
CY2024Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
26537000
CY2023Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
58503000
us-gaap Interest Paid Net
InterestPaidNet
420000
us-gaap Interest Paid Net
InterestPaidNet
2828000
us-gaap Proceeds From Interest Received
ProceedsFromInterestReceived
1721000
us-gaap Proceeds From Interest Received
ProceedsFromInterestReceived
1434000
CY2024Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-369300000
CY2024Q2 us-gaap Cash Cash Equivalents And Short Term Investments
CashCashEquivalentsAndShortTermInvestments
83700000
CY2024Q2 us-gaap Net Income Loss
NetIncomeLoss
-14458000
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
122260000
us-gaap Net Income Loss
NetIncomeLoss
-14047000
us-gaap Net Income Loss
NetIncomeLoss
88384000
CY2024Q2 us-gaap Dilutive Securities Effect On Basic Earnings Per Share Other
DilutiveSecuritiesEffectOnBasicEarningsPerShareOther
0
CY2023Q2 us-gaap Dilutive Securities Effect On Basic Earnings Per Share Other
DilutiveSecuritiesEffectOnBasicEarningsPerShareOther
433000
us-gaap Dilutive Securities Effect On Basic Earnings Per Share Other
DilutiveSecuritiesEffectOnBasicEarningsPerShareOther
0
us-gaap Dilutive Securities Effect On Basic Earnings Per Share Other
DilutiveSecuritiesEffectOnBasicEarningsPerShareOther
1047000
CY2024Q2 us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-14458000
CY2023Q2 us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
122693000
us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-14047000
us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
89431000
CY2024Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
48511656
CY2023Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
47837393
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
48379256
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
47797731
CY2024Q2 us-gaap Incremental Common Shares Attributable To Conversion Of Debt Securities
IncrementalCommonSharesAttributableToConversionOfDebtSecurities
0
CY2023Q2 us-gaap Incremental Common Shares Attributable To Conversion Of Debt Securities
IncrementalCommonSharesAttributableToConversionOfDebtSecurities
1138200
us-gaap Incremental Common Shares Attributable To Conversion Of Debt Securities
IncrementalCommonSharesAttributableToConversionOfDebtSecurities
0
us-gaap Incremental Common Shares Attributable To Conversion Of Debt Securities
IncrementalCommonSharesAttributableToConversionOfDebtSecurities
1138200
CY2024Q2 scyx Incremental Common Shares Attributable To Restricted Stock Units
IncrementalCommonSharesAttributableToRestrictedStockUnits
0
CY2023Q2 scyx Incremental Common Shares Attributable To Restricted Stock Units
IncrementalCommonSharesAttributableToRestrictedStockUnits
947768
scyx Incremental Common Shares Attributable To Restricted Stock Units
IncrementalCommonSharesAttributableToRestrictedStockUnits
0
scyx Incremental Common Shares Attributable To Restricted Stock Units
IncrementalCommonSharesAttributableToRestrictedStockUnits
230320
CY2024Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
48511656
CY2023Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
49923361
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
48379256
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
49166251
CY2024Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.3
CY2023Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
2.46
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.29
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
1.82
CY2024Q2 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
22493164
CY2023Q2 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
24419347
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
22493164
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
24419347
us-gaap Prior Period Reclassification Adjustment Description
PriorPeriodReclassificationAdjustmentDescription
<p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Reclassification of Prior Year Amounts</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Certain prior year amounts within the changes in operating assets and liabilities on the unaudited condensed consolidated statement of cash flows and certain prior year accrued expenses have been reclassified for consistency with the current year presentation.</span></p>
CY2024Q2 scyx Prepaid Researchand Development Expenses Current
PrepaidResearchandDevelopmentExpensesCurrent
0
CY2023Q4 scyx Prepaid Researchand Development Expenses Current
PrepaidResearchandDevelopmentExpensesCurrent
196000
CY2024Q2 us-gaap Prepaid Insurance
PrepaidInsurance
651000
CY2023Q4 us-gaap Prepaid Insurance
PrepaidInsurance
264000
CY2024Q2 us-gaap Other Prepaid Expense Current
OtherPrepaidExpenseCurrent
213000
CY2023Q4 us-gaap Other Prepaid Expense Current
OtherPrepaidExpenseCurrent
182000
CY2024Q2 us-gaap Other Assets Current
OtherAssetsCurrent
554000
CY2023Q4 us-gaap Other Assets Current
OtherAssetsCurrent
4906000
CY2024Q2 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
1418000
CY2023Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
5548000
CY2024Q2 scyx Accrued Researchand Development Expense Current
AccruedResearchandDevelopmentExpenseCurrent
2348000
CY2023Q4 scyx Accrued Researchand Development Expense Current
AccruedResearchandDevelopmentExpenseCurrent
2830000
CY2024Q2 us-gaap Accrued Bonuses Current
AccruedBonusesCurrent
906000
CY2023Q4 us-gaap Accrued Bonuses Current
AccruedBonusesCurrent
1692000
CY2024Q2 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
862000
CY2023Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
1040000
CY2024Q2 scyx Accrued Product Recall
AccruedProductRecall
1382000
CY2023Q4 scyx Accrued Product Recall
AccruedProductRecall
1933000
CY2024Q2 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
5498000
CY2023Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
7495000
CY2023Q2 scyx Amortization Of Remaining Financing Costs And Discounts
AmortizationOfRemainingFinancingCostsAndDiscounts
1700000
scyx Amortization Of Remaining Financing Costs And Discounts
AmortizationOfRemainingFinancingCostsAndDiscounts
2000000
CY2023Q1 scyx Deferred Fees Paid
DeferredFeesPaid
5800000
CY2018Q1 scyx Lease Agreement Area Of Office Space
LeaseAgreementAreaOfOfficeSpace
19275
CY2018Q1 us-gaap Lessee Operating Lease Term Of Contract
LesseeOperatingLeaseTermOfContract
P11Y
CY2018Q1 us-gaap Operating Lease Payments
OperatingLeasePayments
7300000
us-gaap Lessee Operating Lease Option To Extend
LesseeOperatingLeaseOptionToExtend
The Company has the option to renew for two consecutive five-year periods from the end of the first term and the Company is not reasonably certain that the option to renew the Lease will be exercised. Under the Lease, the Company furnished a security deposit in the form of a standby letter of credit in the amount of $0.3 million, which was reduced by fifty-five thousand dollars on the first anniversary of the commencement date. The security deposit will continue to be reduced by fifty-five thousand dollars every two years on the commencement date anniversary for eight years.
CY2018Q1 us-gaap Lessee Operating Lease Existence Of Option To Extend
LesseeOperatingLeaseExistenceOfOptionToExtend
true
CY2018Q1 us-gaap Lessee Operating Lease Renewal Term
LesseeOperatingLeaseRenewalTerm
P5Y
CY2018Q1 us-gaap Security Deposit
SecurityDeposit
300000
CY2018Q1 us-gaap Increase Decrease In Security Deposits
IncreaseDecreaseInSecurityDeposits
55000
CY2024Q2 us-gaap Operating Lease Cost
OperatingLeaseCost
166000
CY2023Q2 us-gaap Operating Lease Cost
OperatingLeaseCost
166000
us-gaap Operating Lease Cost
OperatingLeaseCost
332000
us-gaap Operating Lease Cost
OperatingLeaseCost
332000
CY2024Q2 scyx Variable Lease Cost Credit
VariableLeaseCostCredit
27000
CY2023Q2 scyx Variable Lease Cost Credit
VariableLeaseCostCredit
46000
scyx Variable Lease Cost Credit
VariableLeaseCostCredit
4000
scyx Variable Lease Cost Credit
VariableLeaseCostCredit
104000
CY2024Q2 us-gaap Lease Cost
LeaseCost
193000
CY2023Q2 us-gaap Lease Cost
LeaseCost
212000
us-gaap Lease Cost
LeaseCost
336000
us-gaap Lease Cost
LeaseCost
436000
CY2024Q2 us-gaap Operating Lease Payments
OperatingLeasePayments
181000
CY2023Q2 us-gaap Operating Lease Payments
OperatingLeasePayments
177000
us-gaap Operating Lease Payments
OperatingLeasePayments
362000
us-gaap Operating Lease Payments
OperatingLeasePayments
355000
CY2024Q2 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P5Y1M2D
CY2023Q4 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P5Y7M2D
CY2024Q2 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.15
CY2023Q4 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.15
CY2024Q2 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
368000
CY2024Q2 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
744000
CY2024Q2 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
759000
CY2024Q2 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
774000
CY2024Q2 us-gaap Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
790000
CY2024Q2 scyx Lessee Operating Lease Liability Payments Due After Year Four
LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour
466000
CY2024Q2 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
3901000
CY2024Q2 us-gaap Operating Lease Liability
OperatingLeaseLiability
2760000
CY2024Q2 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
372000
CY2024Q2 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
2388000
CY2024Q2 us-gaap Operating Lease Liability
OperatingLeaseLiability
2760000
CY2024Q2 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
1141000
CY2024Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2023Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2024Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
150000000
CY2023Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
150000000
CY2024Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
37856463
CY2024Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
37856463
CY2023Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
37207799
CY2023Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
37207799
CY2024Q1 us-gaap Stockholders Equity
StockholdersEquity
74105000
CY2024Q2 us-gaap Net Income Loss
NetIncomeLoss
-14458000
CY2024Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
759000
CY2024Q2 us-gaap Stock Issued During Period Value Restricted Stock Award Gross
StockIssuedDuringPeriodValueRestrictedStockAwardGross
0
CY2024Q2 us-gaap Stockholders Equity
StockholdersEquity
60406000
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
-29914000
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
122260000
CY2023Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
728000
CY2023Q2 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
4000
CY2023Q2 us-gaap Stock Issued During Period Value Restricted Stock Award Gross
StockIssuedDuringPeriodValueRestrictedStockAwardGross
0
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
93078000
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
72962000
us-gaap Net Income Loss
NetIncomeLoss
-14047000
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1464000
us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
26000
us-gaap Stock Issued During Period Value Restricted Stock Award Gross
StockIssuedDuringPeriodValueRestrictedStockAwardGross
1000
CY2024Q2 us-gaap Stockholders Equity
StockholdersEquity
60406000
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
3233000
us-gaap Net Income Loss
NetIncomeLoss
88384000
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1435000
us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
4000
us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
4000
us-gaap Stock Issued During Period Value Restricted Stock Award Gross
StockIssuedDuringPeriodValueRestrictedStockAwardGross
18000
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
93078000
CY2024Q2 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
41178848
CY2023Q4 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
40613284
CY2024Q2 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
5800000
CY2023Q2 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-8200000
us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-3800000
us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
13500000
CY2024Q2 scyx Fair Value Of Liabilities
FairValueOfLiabilities
18000000
CY2023Q4 scyx Fair Value Of Liabilities
FairValueOfLiabilities
21800000
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
1867795
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
10.72
CY2023 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P6Y1M6D
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
184000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
1000060
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
1.86
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
25047
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
36.36
CY2024Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
2842808
CY2024Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
7.38
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P7Y14D
CY2024Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
254000
CY2024Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber
1545764
CY2024Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice
11.78
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1
P5Y2M19D
CY2024Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue
59000
CY2024Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
2842808
CY2024Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
7.38
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1
P7Y14D
CY2024Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue
254000
CY2024Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
800000
CY2023Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
700000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1500000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1400000
CY2024Q2 us-gaap Employee Service Share Based Compensation Tax Benefit From Compensation Expense
EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense
0
CY2023Q2 us-gaap Employee Service Share Based Compensation Tax Benefit From Compensation Expense
EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense
0
us-gaap Employee Service Share Based Compensation Tax Benefit From Compensation Expense
EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense
0
us-gaap Employee Service Share Based Compensation Tax Benefit From Compensation Expense
EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense
0
CY2024Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
759000
CY2023Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
728000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1464000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1435000
CY2023Q4 us-gaap Contract With Customer Liability
ContractWithCustomerLiability
2057000
scyx Contract With Customer Liability Provision Related To Current Period Revenue
ContractWithCustomerLiabilityProvisionRelatedToCurrentPeriodRevenue
0
us-gaap Contract With Customer Liability Cumulative Catch Up Adjustment To Revenue Change In Estimate Of Transaction Price
ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice
25000
us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
-589000
CY2024Q2 us-gaap Contract With Customer Liability
ContractWithCustomerLiability
1493000
CY2022Q4 us-gaap Contract With Customer Liability
ContractWithCustomerLiability
1541000
scyx Contract With Customer Liability Provision Related To Current Period Revenue
ContractWithCustomerLiabilityProvisionRelatedToCurrentPeriodRevenue
3143000
us-gaap Contract With Customer Liability Cumulative Catch Up Adjustment To Revenue Change In Estimate Of Transaction Price
ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice
693000
us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
-2129000
CY2023Q2 us-gaap Contract With Customer Liability
ContractWithCustomerLiability
3248000
CY2024Q2 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
1200000
CY2024Q2 us-gaap Deferred Revenue Noncurrent
DeferredRevenueNoncurrent
1800000

Files In Submission

Name View Source Status
0000950170-24-093856-index-headers.html Edgar Link pending
0000950170-24-093856-index.html Edgar Link pending
0000950170-24-093856.txt Edgar Link pending
0000950170-24-093856-xbrl.zip Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
scyx-20240630.htm Edgar Link pending
scyx-20240630.xsd Edgar Link pending
scyx-ex31_1.htm Edgar Link pending
scyx-ex31_2.htm Edgar Link pending
scyx-ex32_1.htm Edgar Link pending
Show.js Edgar Link pending
scyx-20240630_htm.xml Edgar Link completed